Gossamer Bio (NASDAQ:GOSS) Azioni

Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Inc

GOSSAN RESOURCES LTD CDA by Gossan Resources Ltd.

Gossan Resources Ltd

Chicago Fed President Austan Goolsbee has voiced serious concerns over President Donald Trump's recent remarks about removing Federal Reserve Chair Jerome Powell. What Happened: Trump's comments, made following <a href="https://fortune.com/2025/04/16/jerome-powell-tariffs-inflation-economy/">Powell's speech</a> at the Economic Club of Chicago, reignited a long-standing debate over the President's power to remove Federal Reserve leaders.
Goolsbee warned that such an action could severely undermine the credibility of the U.S. central bank, with far-reaching consequences for economic stability, as reported <a href="https://fortune.com/article/chicago-fed-president-austan-goolsbee-trump-terminate-jerome-powell-undermine-fed-credibility/">by</a> Fortune on Monday.
Trump has repeatedly criticized Powell for not cutting interest rates quickly enough in response to economic conditions, particularly following his controversial tariff policies.
Powell has argued that the tariff increases announced by Trump have significantly impacted inflation and economic growth, which led to his warnings.
Trump has blamed Powell for not acting swiftly enough to ease interest rates, which he believes are necessary to counter the negative economic effects of his policies.
See Also: <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44883642/peter-schiff-rings-alarm-after-foreign-investors-dump-6-5-billion-in-us-equities-in" target="_blank" rel="noreferrer noopener">Peter Schiff Rings Alarm After Foreign Investors Dump $6.5 Billion In US Equities In A Week, Quips &#8216;Trump Thought Tariffs Would Bring Capital Into America&#8217;</a>
This conflict has drawn attention. Goolsbee, echoing the concerns of many economists, cautioned that removing Powell could set a dangerous precedent that could erode trust in the Fed.
"I strongly hope that we do not move ourselves into an environment where monetary independence is questioned," Goolsbee stated, highlighting the importance of keeping the Federal Reserve free from political influence.
Why It Matters: Trump&#8217;s criticism of Powell and his intention to terminate him have been a topic of concern for some time. Trump <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44861571/donald-trump-blasts-too-late-and-wrong-fed-chair-powell-but-polymarket-traders-doubt-his-termination-will-come-fast-enough">lashed out at Powell</a> for the Federal Reserve&#8217;s reluctance to cut interest rates.
This was followed by <a href="https://www.benzinga.com/markets/25/04/44883756/warren-foresees-market-turmoil-if-trump-dismisses-feds-powell-if-powell-can-be-fired-by-trump-it-will-crash-markets">Senator Elizabeth Warren&#8217;s warning</a> about a potential stock market collapse if Trump decides to fire Powell.
Investment strategists have also&nbsp;<a href="https://www.benzinga.com/news/25/04/44882256/trumps-threat-to-fire-powell-could-shake-us-financial-markets">warned</a>&nbsp;that Trump&#8217;s potential attempt to dismiss Powell could rattle U.S. financial markets and undermine central bank independence. Furthermore,&nbsp;<a href="https://www.benzinga.com/25/04/44888232/trumps-top-economic-adviser-kevin-hassett-says-white-house-is-exploring-options-to-fire-fed-chair-jerome-powell-the-president-and-his-team-will-continue-to-study">White House National Economic Council chair Kevin Hassett</a>&nbsp;confirmed that the Trump administration is exploring ways to remove Powell, adding to the uncertainty. Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44891314/dhl-says-its-suspending-global-shipments-to-us-valued-more-than-800-as-customs-updates-cause-multi-day-transit-de" target="_blank" rel="noreferrer noopener">DHL Says It&#8217;s Suspending Global Shipments To US Valued More Than $800 As Customs Updates Cause Multi-Day Transit Delays</a></li>
</ul>
Photo courtesy: Domenico Fornas / Shutterstock.com

News

Politics

Chicago Fed President Expresses Concern Over Trump's Intention To Dismiss Jerome Powell

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Market Perform and lowers the price target from $47 to $42.

Price Target

Analyst Ratings

FITB

Keefe, Bruyette & Woods Maintains Market Perform on Fifth Third Bancorp, Lowers Price Target to $42

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) with a Market Perform and lowers the price target from $38 to $36.

FFIN

Keefe, Bruyette & Woods Maintains Market Perform on First Finl Bankshares, Lowers Price Target to $36

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and raises the price target from $19 to $20.

PSTV

Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) with a Market Perform and lowers the price target from $75 to $73.

BANR

Keefe, Bruyette & Woods Maintains Market Perform on Banner, Lowers Price Target to $73

Keefe, Bruyette &amp; Woods analyst Kelly Motta upgrades F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) from Market Perform to Outperform and maintains the price target from $16.5 to $16.5.

Upgrades

Keefe, Bruyette & Woods Upgrades F N B to Outperform, Maintains Price Target to $16.5

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) with a Buy and raises the price target from $19 to $19.5.

PAVM

Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $19.5

Baird analyst Jonathan Komp upgrades Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) from Neutral to Outperform and maintains the price target from $15 to $15.

Baird Upgrades Wolverine World Wide to Outperform, Maintains Price Target to $15

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and raises the price target from $7 to $7.5.

LUCD

Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $7.5

Investar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.43 by 48.84 percent. This is a 48.84 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $20.36 million which beat the analyst consensus estimate of $19.90 million by 2.29 percent. This is a 10.11 percent decrease over sales of $22.65 million the same period last year.

Earnings

ISTR

Investar Holding Q1 2025 Adj EPS $0.64 May Not Be Comparable To $0.43 Estimate, Sales $20.36M Beat $19.90M Estimate

NESR

NESR Breaks Ground on 180,000m² Facility At King Salman Energy Park, Pioneering Innovation In Saudi Arabia's Oilfield Services

Global real estate investment company Kennedy Wilson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KW#NYSE">KW</a>) has partnered with Tokyu Land US Corporation, a wholly owned subsidiary of Tokyu Land Corporation (Tokyu), one of Japan's largest real estate developers, to launch a new preferred equity and mezzanine real estate investment platform. The expanded credit solution focus will further scale Kennedy Wilson's thriving credit platform.
Kennedy Wilson and Tokyu will target over $200 million in investments with a focus on preferred equity investments and mezzanine loans to high-quality sponsors across multifamily and industrial projects nationwide. The platform is targeting markets with strong and growing local economies, attractive local amenities, and proximity to employment prospects. The platform's target investment size will generally range between $10 million and $50 million. Each investment within the platform will be approved by both Tokyu and Kennedy Wilson and Kennedy Wilson will hold 10% of the venture.

Kennedy Wilson Partners with Tokyu Land For New $200M Real Estate Investment Focus

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) co-founder&nbsp;Vitalik Buterin&nbsp;proposed a long-term solution Sunday to improve the scalability and efficiency of the network&#8217;s execution layer, one that handles smart contracts and transactions.
What Happened: In a blog post, Buterin <a href="https://ethereum-magicians.org/t/long-term-l1-execution-layer-proposal-replace-the-evm-with-risc-v/23617">suggested </a>replacing the&nbsp;Ethereum Virtual Machine contract&nbsp;language with the open-source RISC-V instruction&nbsp;set architecture. This, he argued, would address long-term scaling bottlenecks like keeping block production competitive and enhancing the efficiency of zero-knowledge EVM proving—a vital feature that enables off-chain computation and verification of transactions.
Buterin theorized that implementing the said proposal could, in limited cases, generate efficiency gains of over 100x.
See Also: <a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"></a><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44891685/gary-black-shares-polymarket-data-says-trump-tariffs-have-pushed-odds-of-2025-recession-to-57">Gary Black Shares Polymarket Data, Says Trump Tariffs Have Pushed Odds Of 2025 Recession To 57%</a>
Why It Matters: Buterin&#8217;s proposal comes at a time when the Ethereum base layer was battling a sharp dip in transaction activity and fees.
According to Etherscan, ETH&#8217;s average transaction fees have <a href="https://etherscan.io/chart/avg-txfee-usd">slipped </a>to levels not seen since May 2020. Typically, this happens due to <a href="https://www.benzinga.com/money/ethereum-gas-fees">low network demand</a>. 
Since a portion of the transaction fees is burned to add deflationary pressure to ETH, the drop in fees resulted in a lower number of ETH removed from circulation and, subsequently, inflation, <a href="https://ultrasound.money/?timeFrame=since_merge">according </a>to Ultrasound Money.
Analysts interviewed by Benzinga attributed this to the rise of Layer-2 blockchains and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37667987/ethereum-dencun-upgrade-drops-layer-2-fees-by-99">Dencun Upgrade</a>, which significantly reduced transaction costs on L2s. This resulted in on-chain activity being diverted away from the Ethereum foundation chain.
Price Action: At the time of writing, Ethereum was exchanging hands at $1,644.66, up 3.28% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.&nbsp;Year-to-date, the coin has plunged more than 50%.
Read Next
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44890965/shiba-inu-team-issues-major-anti-scam-alert-heres-what-you-need-to-know">Shiba Inu Team Issues Major Anti-Scam Alert: Here&#8217;s What You Need To Know</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Image Via Shutterstock/VPLAB

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$ETH

Vitalik Buterin Suggests Major Overhaul To Improve Ethereum's Network Efficiency As Transaction Fees Plunge To 5-Year Lows

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and raises the price target from $7 to $7.25.

ATOS

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25

General

HITI

High Tide Opens New Canna Cabana Retail Stores In Cochrane, Alberta

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW)),&nbsp;a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates."
"Chronic low back pain is a complex problem that is complicated to diagnose," said Doug Beall, MD, Chief of Radiology Services, Clinical Radiology of Oklahoma and co-author.&nbsp;"I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. The profound conclusions within this important paper will not only benefit surgical intervention, but also my non-surgical colleagues in Pain Management and Interventional Radiology. Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography."
ClinicoEconomics and Outcomes Research&nbsp;is a&nbsp;peer-reviewed&nbsp;healthcare journal&nbsp;focusing on covering the economic impact of health policy and health systems organization. The journal was established in 2009 and is published by&nbsp;Dove Medical Press.
"We are pleased with the cost-effectiveness results illustrated in this important paper," said Ryan Bond, Chief Strategy Officer at Aclarion. "We believe the results demonstrating Nociscan's economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare."
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain.

ACON

Aclarion's AI-Powered Nociscan Proves More Cost-Effective for Chronic Back Pain Diagnosis

Offerings

DOMH

Dominari Holdings  Filed For Offering Of Up To 13.94M Shares By Selling Stockholders

Earnings Misses

Ennis Q4 2024 GAAP EPS $0.35 Misses $0.37 Estimate, Sales $92.701M Miss $95.600M Estimate

Ascendiant Capital analyst Edward Woo maintains Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) with a Buy and lowers the price target from $13 to $12.

Comments

Gossamer Bio

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO